About this trial
This study aimed to evaluate the effectiveness of a precision cryotherapy via boosting mode combined with tranexamic acid versus normal saline in the treatment of melasma. Eighteen patients aged 25 to 60 years diagnosed with epidermal-typed melasma sized equal to or more than 2 cm on both cheeks were included. The patients were treated with a precision cryotherapy via boosting mode combined with tranexamic acid and normal saline on each side of cheek for 4 times every 1 week. Then, they were follow up at 1 and 3 months after the last treatment. Subjective assessment of physician and patient improvement were evaluated. Moreover, Melasma Area and Severity Index (MASI), melanin and erythema index using Mexameter were also recorded.
Eligibility criteria
Qualifiers
The patients diagnosed with epidermal-type melasma sized equal to or more than 2 cm on both sides of cheeks
Fitzpatrick skin type II-IV
Disqualifiers
Pregnant or lactation
Subjects who have been treated with any kind of energy-based device 6 months prior to the inclusion
Subjects who have been treated with topical or oral treatment for melasma 6 months prior to the inclusion
Subjects who allergy to cryotherapy such as cryoglobulinemia, cold urticaria, and abnormal cold tolerance
Trial design
Treatments tested in this trial
- TargetCool